How to Get Testosterone Cypionate in Arkansas

Who Can Prescribe Testosterone Cypionate in Arkansas

Any physician (MD or DO) licensed by the Arkansas State Medical Board can prescribe testosterone cypionate for documented male hypogonadism. Arkansas also permits nurse practitioners and physician assistants to prescribe Schedule III controlled substances, though NPs must maintain a collaborative practice agreement with a supervising physician under Arkansas Code § 17-87-310.

Prescribing authority matters because testosterone cypionate is a Schedule III controlled substance under the DEA Controlled Substances Act. The prescriber must hold an active DEA registration and comply with Arkansas Department of Health reporting requirements through the state's Prescription Drug Monitoring Program (PDMP). Every testosterone cypionate prescription filled in Arkansas generates a PDMP entry that the prescriber and pharmacist can review.

Endocrinologists and urologists most commonly manage testosterone replacement therapy (TRT), but primary care physicians, family medicine doctors, and men's health clinicians also prescribe it regularly. A 2020 analysis published in JAMA Network Open found that primary care providers wrote approximately 50% of all testosterone prescriptions in the United States (JAMA Network Open, 2020). This pattern holds in Arkansas, where specialist access is limited outside Little Rock, Fayetteville, and Fort Smith.

Telehealth Access for Testosterone Cypionate in Arkansas

Arkansas permits testosterone cypionate prescribing via telehealth. The state adopted permanent telehealth legislation (Act 829 of 2021) that allows licensed prescribers to evaluate, diagnose, and prescribe medications, including Schedule III controlled substances, through audio-video consultations. A phone-only visit is not sufficient for an initial controlled substance prescription.

The telehealth pathway works well for patients in rural counties. Arkansas has 75 counties, and many lack a local endocrinologist. Telehealth platforms that employ Arkansas-licensed providers can serve patients anywhere in the state, provided the initial visit includes a synchronous video component and the provider reviews qualifying lab work.

Here is how a typical telehealth TRT process works in Arkansas:

1. Complete an intake questionnaire and upload recent lab results (or receive a lab order).
2. Attend a video consultation with an Arkansas-licensed prescriber.
3. Receive a prescription sent electronically to your pharmacy of choice.
4. Pick up or receive your medication, typically within 3-7 business days after the prescription is transmitted.

The Endocrine Society's 2018 clinical practice guideline recommends against prescribing testosterone to men who have not had at least two morning serum testosterone measurements confirming levels below 300 ng/dL, along with signs and symptoms of hypogonadism (Bhasin et al., Journal of Clinical Endocrinology & Metabolism, 2018). Telehealth providers operating in Arkansas follow these same diagnostic thresholds.

Required Lab Work Before Starting Testosterone Cypionate

Lab testing is not optional. Before any Arkansas provider will prescribe testosterone cypionate, you need a specific set of blood tests drawn during the morning hours (ideally between 7:00 AM and 10:00 AM), when testosterone levels peak.

Minimum labs required before first prescription:

• Total testosterone (two separate morning draws, taken on different days)
• Free testosterone or bioavailable testosterone
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel (CMP)
• Lipid panel
• Prostate-specific antigen (PSA) for men over 40
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to differentiate primary from secondary hypogonadism

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that testosterone gel improved sexual function, physical activity, and mood over 12 months (Snyder et al., NEJM, 2016). These trials also underscored the importance of baseline cardiovascular and hematologic screening, as hematocrit elevation was the most common adverse finding requiring dose adjustment.

Quest Diagnostics and Labcorp both operate draw sites across Arkansas, including locations in Little Rock, Jonesboro, Pine Bluff, Bentonville, and Texarkana. Many telehealth TRT providers will send lab orders directly to one of these networks. Expect to pay $0-50 with insurance or $75-200 out of pocket for the full panel.

Testosterone Cypionate Dosing and Administration

The FDA-approved prescribing information for testosterone cypionate specifies a dose range of 50-400 mg administered intramuscularly every 2-4 weeks for male hypogonadism. Current clinical practice, however, has shifted toward more frequent, lower-dose protocols.

Most TRT providers now prescribe 100-200 mg per week, administered as a single weekly intramuscular injection or divided into two subcutaneous injections of 50-100 mg each. The twice-weekly protocol produces more stable serum testosterone levels with fewer peaks and troughs. A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism showed that weekly dosing of testosterone cypionate maintained serum testosterone within the physiologic range (400-700 ng/dL) more consistently than biweekly dosing (Nankin, 1987).

Subcutaneous injection has gained acceptance as an alternative to intramuscular delivery. A 2014 study in Translational Andrology and Urology found that subcutaneous testosterone cypionate injections achieved comparable serum levels to intramuscular injections while patients reported less injection-site pain (Al-Futaisi et al., 2014). Many Arkansas providers now offer patients the choice between IM and SubQ routes.

Standard testosterone cypionate is supplied in 200 mg/mL concentration, in either 1 mL or 10 mL multi-dose vials. The oil carrier is typically cottonseed oil, though 503A compounding pharmacies can prepare formulations in grapeseed oil or sesame oil for patients with cottonseed allergies.

503A Compounding Pharmacies in Arkansas

Arkansas licenses 503A compounding pharmacies under the Arkansas State Board of Pharmacy. These pharmacies can compound testosterone cypionate in custom concentrations, alternative carrier oils, and combination formulations (such as testosterone cypionate with anastrozole) based on a valid patient-specific prescription.

Three things distinguish 503A compounded testosterone from commercial generic:

Custom concentration. While commercial vials come in 200 mg/mL, a compounding pharmacy can prepare 100 mg/mL or 150 mg/mL concentrations for patients who need smaller, more precise dose adjustments.

Alternative carriers. Patients allergic to cottonseed oil can receive testosterone cypionate compounded in grapeseed oil or MCT oil.

Cost. Compounded testosterone cypionate often costs $40-80 for a 10 mL vial (a 10-20 week supply at typical doses), compared to $30-90 for commercial generic through insurance copay, or $80-150 cash price at retail pharmacies.

Arkansas 503A pharmacies can ship compounded testosterone within the state. They cannot ship across state lines unless they hold a 503B outsourcing facility registration with the FDA. For in-state patients, several compounding pharmacies in Little Rock, Rogers, and Hot Springs fill testosterone cypionate prescriptions and offer direct mail delivery.

Insurance Coverage and Prior Authorization in Arkansas

Most commercial insurance plans in Arkansas cover generic testosterone cypionate for the FDA-approved indication of male hypogonadism. The typical patient cost is a Tier 1 or Tier 2 copay of $10-30 for a 10 mL vial.

Arkansas Medicaid covers testosterone cypionate with prior authorization (PA). The PA process requires documentation of:

• A confirmed diagnosis of hypogonadism (ICD-10 code E29.1)
• Two morning serum total testosterone levels below 300 ng/dL
• Clinical signs and symptoms (fatigue, decreased libido, erectile dysfunction, loss of muscle mass, depressed mood)
• Notation that the patient does not have contraindications including breast or prostate cancer, untreated polycythemia, or severe untreated sleep apnea

The American Urological Association (AUA) 2018 guideline for testosterone deficiency states that treatment should be offered to men with "unequivocally low serum testosterone levels, measured on at least two occasions," combined with clinical symptoms (Mulhall et al., Journal of Urology, 2018). Insurance companies in Arkansas follow these same criteria when evaluating PA requests.

PA turnaround in Arkansas typically takes 3-7 business days. If denied, your prescriber can submit a peer-to-peer review. Denials are most commonly due to incomplete lab documentation (submitting only one testosterone level instead of two) or failure to document symptoms.

For patients paying cash without insurance, GoodRx and similar discount programs price generic testosterone cypionate 200 mg/mL (10 mL vial) at approximately $40-80 at major Arkansas chain pharmacies including Walgreens, CVS, and Walmart.

Monitoring and Follow-Up Requirements

Starting testosterone cypionate is not a one-time event. The Endocrine Society guideline recommends follow-up labs at 3-6 months after starting therapy, then annually (Bhasin et al., 2018).

Follow-up labs should include:

• Serum total testosterone (drawn midway between injections, or trough level for weekly dosing)
• Hematocrit and hemoglobin (to monitor for polycythemia; dose reduction or temporary hold is recommended if hematocrit exceeds 54%)
• PSA (for men over 40)
• Lipid panel
• Estradiol (if symptoms of estrogen excess develop)

The TRAVERSE trial (N=5,246), published in NEJM in 2023, was the first large cardiovascular safety trial of testosterone replacement. It found that testosterone 1.62% gel did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45-80 with hypogonadism and pre-existing or high risk of cardiovascular disease (hazard ratio 0.99; 95% CI, 0.81-1.21) (Lincoff et al., NEJM, 2023). This trial shifted the risk-benefit conversation, though monitoring for hematocrit elevation and cardiovascular risk factors remains standard practice.

Hematocrit elevation is the most common reason for dose adjustment. A study in Clinical Endocrinology reported that 11.2% of men on injectable testosterone developed hematocrit levels above 54% within the first year, compared to 5.5% of men on transdermal testosterone (Bachman et al., 2014). Arkansas providers typically recommend therapeutic phlebotomy or dose reduction if hematocrit exceeds 52-54%.

Timeline from Consultation to First Injection

The entire process, from initial consultation to first injection, typically takes 7-14 days in Arkansas. Here is a realistic breakdown:

• Days 1-3: Complete intake, receive lab order, get blood drawn at a local lab
• Days 3-7: Lab results return; video or in-person consultation with prescriber
• Day 7-10: Prescription sent to pharmacy; pharmacy fills and dispenses or ships
• Day 10-14: First injection (self-administered at home or at provider's office)

Patients who already have qualifying lab work (drawn within the past 6 months showing total testosterone below 300 ng/dL on two separate occasions) can compress this timeline to 3-7 days. Telehealth platforms tend to move faster than traditional brick-and-mortar clinics because they process intake digitally and use e-prescribing.

Legal Considerations Specific to Arkansas

Testosterone cypionate is a Schedule III controlled substance under both federal and Arkansas state law. Possessing it without a valid prescription is a Class D felony in Arkansas. Prescriptions for Schedule III substances in Arkansas are valid for up to 6 months from the date written and may include up to 5 refills within that period.

Arkansas requires prescribers to check the PDMP before issuing an initial testosterone prescription. This requirement was established under Act 820 of 2017 and applies to all Schedule II-V controlled substances. The PDMP check ensures that the patient is not receiving testosterone or other controlled substances from multiple providers simultaneously.

Arkansas does not restrict telemedicine prescribing of testosterone cypionate beyond the standard requirement of a synchronous audio-video evaluation for the initial visit. Follow-up visits may be conducted via phone or video. The state does not require an in-person visit before initiating a controlled substance prescription, as long as the standard of care is met through the telehealth encounter.